Recent comments from Trump’s FDA commissioner, coupled with an anti-abortion study on mifepristone, are setting off alarm bells among reproductive rights groups.

By May 5, 2025, the Trump administration will file its first brief in <i>Missouri v. Food</i> and Drug Administration, staking out a position in the case on whether it will continue to defend the Food and Drug Administration’s regulation of mifepristone.

Recent comments from Trump’s FDA commissioner, coupled with an anti-abortion study on mifepristone, are setting off alarm bells among reproductive rights groups.

By May 5, 2025, the Trump administration will file its first brief in <i>Missouri v. Food</i> and Drug Administration, staking out a position in the case on whether it will continue to defend the Food...

By May 5, 2025, the Trump administration will file its first brief in <i>Missouri v. Food</i> and Drug Administration, staking out a position in the case on whether it will continue to defend the Food...

The Trump administration has issued a final market stabilization rule. Stabilizing the individual and small group markets is an important concern, as many counties will have only one insurer next year. Does the rule do what’s needed, and what threats to market stability does it leave unaddressed?

This article does not attempt to predict the potential policies that the new administration and Congress might pursue or how they will set priorities. Instead, this article discusses the various near-...